Post Analytic Treatment Interruption Study

NCT ID: NCT02761200

Last Updated: 2023-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2031-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring. Participants without any indication for resumption of ART and who desire to remain off ART at the time of entry into this study will be monitored closely for HIV viremia and other pre-defined criteria for ART resumption. Participants with any indication for ART at the time of enrollment into this protocol, including patient preference for resumption of ART, will be monitored closely for virologic and immunologic response to ART.

Clinical study visits will take place at the Thai Red Cross AIDS Research Centre, and the optional procedures may occur at the King Chulalongkorn Memorial Hospital. Required laboratory studies that are outlined in this protocol will occur in lieu of those described in the RV 254 protocol. Volunteers may provide separate informed consent for optional procedures to include collection of genital secretions, colon biopsy, inguinal lymph node biopsy, cerebrospinal fluid (CSF) collection via lumbar puncture, and brain Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS)/Diffusion Tensor Imaging (DTI). With separate informed consent, willing participants will undergo archival of peripheral blood mononuclear cells and plasma specimens for research purposes.

This study will enroll volunteers aged 18 years and older who have completed clinical studies that include ATI in Bangkok, Thailand. Enrollment in this study will be concurrent with completion of the study with ATI. Participants will fall broadly into one of two categories: those on ART and those not on ART at the completion of the prior study protocol.

The ongoing parent study, RV 254 (SEARCH 010, WRAIR 1494), enrolls participants with documented acute HIV infection at the Thai Red Cross AIDS Research Center in Bangkok, Thailand. Participants in the cohort are primarily men who have sex with men, but also include men and women with other HIV acquisition risk factors as well as various ages, incomes, and education levels. All participants in RV 254 are offered ART at the time of enrollment through a separately funded protocol. Participants in this substudy will remain co-enrolled in RV254/SEARCH010, but will follow the schedule of event (SOE) for this sub-study in lieu of the parent study SOE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

volunteer who completion of a recent ATI

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman aged ≥18 years.
* Enrolled in RV254 study.
* Completed clinical research protocol that included ATI within one month of enrollment in this protocol.
* Able and willing to provide written informed consent or, in the case of illiteracy, witnessed verbal informed consent with documentation of a thumbprint in lieu of a signature.
* Able to participate in study visits for up to 144 weeks.
* Willing to have photo or fingerprint taken for identification purposes.
* Female-specific criteria: Agrees not to become pregnant while not receiving ART. If a woman is sexually active and has no history of hysterectomy or tubal ligation or menopause, she must agree to engage in abstinence, use a prescription birth control method or use a barrier birth control method while not receiving ART.

Exclusion Criteria

* History of a medical or psychiatric condition that, in the opinion of investigator, would jeopardize the safety or rights of the subject, such as a condition that would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

US Military HIV Research Program

NETWORK

Sponsor Role collaborator

SEARCH Research Foundation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nittaya Phanuphak

Nittaya Phanuphak, MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nittaya Phanuphak, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

SEARCH Research Foundation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

SEARCH

Bangkok, , Thailand

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nittaya Phanuphak, MD, PhD

Role: CONTACT

Nitiya Chomchey, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nittaya Phanuphak, MD, PhD

Role: primary

+6622542566

Nitiya Chomchey, MSc

Role: backup

+6622542566 ext. 111

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SEARCH 025/RV412

Identifier Type: -

Identifier Source: org_study_id